{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:59:35Z","timestamp":1788544775801,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA283699-02"],"award-info":[{"award-number":["5R01CA283699-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01CA227277-05"],"award-info":[{"award-number":["5R01CA227277-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.urolonc.2024.10.003","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:04:56Z","timestamp":1740053096000},"page":"88-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Natural history of bladder cancer: Validation of the multiple pathway model in multi-omics era"],"prefix":"10.1016","volume":"43","author":[{"given":"Stacy","family":"Bedore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinata B.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0001","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0011-3840(81)80002-0","article-title":"Bladder cancer","volume":"18","author":"Droller","year":"1981","journal-title":"Curr Probl Surg"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.003_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3322\/canjclin.48.5.269","article-title":"Bladder cancer: state-of-the-art care","volume":"48","author":"Droller","year":"1998","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0003","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00042307-200007000-00002","article-title":"Current concepts in assessment and treatment of bladder cancer","volume":"10","author":"Hassen","year":"2000","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0004","first-page":"177","article-title":"Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms","volume":"11","author":"Jones","year":"1993","journal-title":"Semin Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.003_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0094-0143(05)70229-9","article-title":"The natural history of bladder cancer. Implications for therapy","volume":"27","author":"Lee","year":"2000","journal-title":"Urol Clin North Am"},{"issue":"5 Suppl","key":"10.1016\/j.urolonc.2024.10.003_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.urology.2005.06.128","article-title":"Biological considerations in the assessment of urothelial cancer: a retrospective","volume":"66","author":"Droller","year":"2005","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.003_bib0007","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1469-185X.1975.tb01057.x","article-title":"The mammalian urinary bladder: an accommodating organ","volume":"50","author":"Hicks","year":"1975","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.003_bib0008","doi-asserted-by":"crossref","first-page":"F1477","DOI":"10.1152\/ajprenal.00327.2009","article-title":"Cell biology and physiology of the uroepithelium","volume":"297","author":"Khandelwal","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.urolonc.2024.10.003_bib0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-030-14366-4_8","article-title":"Urothelial Cancer Stem Cell Heterogeneity","volume":"1139","author":"Kripnerova","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.10.003_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112578","article-title":"Molecular Oncology of Bladder Cancer from Inception to Modern Perspective","volume":"14","author":"Lokeshwar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.003_bib0011","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ncb2956","article-title":"Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma","volume":"16","author":"Shin","year":"2014","journal-title":"Nat Cell Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0012","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccell.2014.09.001","article-title":"Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors","volume":"26","author":"Shin","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.urolonc.2024.10.003_bib0013","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/ncb3038","article-title":"Bladder cancers arise from distinct urothelial sub-populations","volume":"16","author":"Van Batavia","year":"2014","journal-title":"Nat Cell Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0014","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/stem.1625","article-title":"A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors","volume":"32","author":"Dancik","year":"2014","journal-title":"Stem Cells"},{"issue":"7","key":"10.1016\/j.urolonc.2024.10.003_bib0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urolonc.2018.02.017","article-title":"The evolution of bladder cancer genomics: what have we learned and how can we use it?","volume":"36","author":"Audenet","year":"2018","journal-title":"Urol Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2024.10.003_bib0016","first-page":"8241","article-title":"Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma","volume":"61","author":"Hoglund","year":"2001","journal-title":"Cancer Res"},{"issue":"33","key":"10.1016\/j.urolonc.2024.10.003_bib0017","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.urolonc.2024.10.003_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-019-0772-8","article-title":"Clinical and Genomic Considerations for Variant Histology in Bladder Cancer","volume":"21","author":"Matulay","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"16","key":"10.1016\/j.urolonc.2024.10.003_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21165670","article-title":"Evolution of urothelial bladder cancer in the context of molecular classifications","volume":"21","author":"Minoli","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.urolonc.2024.10.003_bib0020","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.urolonc.2024.10.003_bib0021","doi-asserted-by":"crossref","first-page":"e48993","DOI":"10.1371\/journal.pone.0048993","article-title":"A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer","volume":"7","author":"Neuzillet","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.003_bib0022","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/CBM-2012-0254","article-title":"The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer","volume":"10","author":"Ouerhani","year":"2011","journal-title":"Cancer Biomark"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.003_bib0023","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2024.10.003_bib0024","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euros.2022.02.004","article-title":"STAG2 protein expression in non-muscle-invasive bladder cancer: associations with sex, genomic and transcriptomic changes, and clinical outcomes","volume":"38","author":"Gordon","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.003_bib0025","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Lee","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.urolonc.2024.10.003_bib0026","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/hmg\/ddt589","article-title":"Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes","volume":"23","author":"Taylor","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.003_bib0027","doi-asserted-by":"crossref","first-page":"15477","DOI":"10.1038\/s41598-018-33761-9","article-title":"Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma","volume":"8","author":"Matsuda","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.003_bib0028","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/JU.0000000000000351","article-title":"Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA","volume":"203","author":"Morera","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.003_bib0029","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","article-title":"Association of molecular subtypes with pathologic response, PFS, and OS in a phase ii study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"30","author":"Lerner","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2024.10.003_bib0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.urolonc.2020.01.019","article-title":"Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer","volume":"40","author":"Cooley","year":"2022","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0031","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.003_bib0032","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.003_bib0033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/path.6266","article-title":"TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1\/PD-L1 blockade response in urothelial carcinoma","volume":"263","author":"Jin","year":"2024","journal-title":"J Pathol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T12:40:58Z","timestamp":1740660058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1078143924006847"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural history of bladder cancer: Validation of the multiple pathway model in multi-omics era","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}